Literature DB >> 27096030

Status of colitis-associated cancer in ulcerative colitis.

Tetsushi Kinugasa1, Yoshito Akagi1.   

Abstract

Surgical therapy for ulcerative colitis (UC) depends on the medical therapy administered for the patient's condition. UC is a benign disease. However, it has been reported that the rare cases of cancer in UC patients are increasing, and such cases have a worse prognosis. Recently, surgical therapy has greatly changed, there has been quite an increase in the number of UC patients with high-grade dysplasia and/or cancer. These lesions are known as colitis-associated cancer (CAC). The relationship between inflammation and tumorigenesis is well-established, and in the last decade, a great deal of supporting evidence has been obtained from genetic, pharmacological, and epidemiological studies. Inflammatory bowel disease, especially UC, is an important risk factor for the development of colon cancer. We should determine the risk factors for UC patients with cancer based on a large body of data, and we should attempt to prevent the increase in the number of such patients using these newly identified risk factors in the near future. Actively introducing the surgical treatment in addition to medical treatment should be considered. Several physicians should analyze UC from their unique perspectives in order to establish new clinically relevant diagnostic and treatment methods in the future. This article discusses CAC, including its etiology, mechanism, diagnosis, and treatment in UC patients.

Entities:  

Keywords:  Colitis-associated cancer; Colorectal cancer surveillance; Inflammatory bowel disease; Surgical therapy; Ulcerative colitis

Year:  2016        PMID: 27096030      PMCID: PMC4824713          DOI: 10.4251/wjgo.v8.i4.351

Source DB:  PubMed          Journal:  World J Gastrointest Oncol


  50 in total

1.  The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Current management.

Authors:  A Dignass; G Van Assche; J O Lindsay; M Lémann; J Söderholm; J F Colombel; S Danese; A D'Hoore; M Gassull; F Gomollón; D W Hommes; P Michetti; C O'Morain; T Oresland; A Windsor; E F Stange; S P L Travis
Journal:  J Crohns Colitis       Date:  2010-01-15       Impact factor: 9.071

2.  Risk of colorectal cancer in patients with ulcerative colitis: a meta-analysis of population-based cohort studies.

Authors:  Tine Jess; Christine Rungoe; Laurent Peyrin-Biroulet
Journal:  Clin Gastroenterol Hepatol       Date:  2012-01-28       Impact factor: 11.382

3.  Cicatrizing enteritis as a pathologic entity; analysis of 120 cases.

Authors:  S WARREN; S C SOMMERS
Journal:  Am J Pathol       Date:  1948-05       Impact factor: 4.307

4.  Local complications of ulcerative colitis. Stricture, pseudopolyps and cancer of the colon and rectum.

Authors:  F T de Dombal; J M Watts; G Watkinson; J C Goligher
Journal:  Am J Proctol       Date:  1967-06

Review 5.  Mucosal healing in inflammatory bowel diseases: a systematic review.

Authors:  Markus F Neurath; Simon P L Travis
Journal:  Gut       Date:  2012-07-27       Impact factor: 23.059

6.  The risk of colorectal cancer in ulcerative colitis: a meta-analysis.

Authors:  J A Eaden; K R Abrams; J F Mayberry
Journal:  Gut       Date:  2001-04       Impact factor: 23.059

7.  Decreasing risk of colorectal cancer in patients with inflammatory bowel disease over 30 years.

Authors:  Tine Jess; Jacob Simonsen; Kristian Tore Jørgensen; Bo Vestergaard Pedersen; Nete Munk Nielsen; Morten Frisch
Journal:  Gastroenterology       Date:  2012-04-19       Impact factor: 22.682

8.  Dysplasia-associated lesion or mass (DALM) detected by colonoscopy in long-standing ulcerative colitis: an indication for colectomy.

Authors:  M O Blackstone; R H Riddell; B H Rogers; B Levin
Journal:  Gastroenterology       Date:  1981-02       Impact factor: 22.682

Review 9.  Carcinogenesis in IBD: potential targets for the prevention of colorectal cancer.

Authors:  Linda A Feagins; Rhonda F Souza; Stuart J Spechler
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2009-05       Impact factor: 46.802

10.  Severity of inflammation is a risk factor for colorectal neoplasia in ulcerative colitis.

Authors:  Matthew Rutter; Brian Saunders; Kay Wilkinson; Steve Rumbles; Gillian Schofield; Michael Kamm; Christopher Williams; Ashley Price; Ian Talbot; Alastair Forbes
Journal:  Gastroenterology       Date:  2004-02       Impact factor: 22.682

View more
  23 in total

1.  Sodium selenite ameliorates both intestinal and extra-intestinal changes in acetic acid-induced colitis in rats.

Authors:  Samar M Soliman; Walaa Wadie; Samia A Shouman; Afaf A Ainshoka
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2018-04-14       Impact factor: 3.000

Review 2.  Guanylate cyclase C as a target for prevention, detection, and therapy in colorectal cancer.

Authors:  Allison A Aka; Jeff A Rappaport; Amanda M Pattison; Takami Sato; Adam E Snook; Scott A Waldman
Journal:  Expert Rev Clin Pharmacol       Date:  2017-04-10       Impact factor: 5.045

3.  Emu Oil Improves Clinical Indicators of Disease in a Mouse Model of Colitis-Associated Colorectal Cancer.

Authors:  Lauren C Chartier; Gordon S Howarth; Ian C Lawrance; Debbie Trinder; Scott J Barker; Suzanne Mashtoub
Journal:  Dig Dis Sci       Date:  2017-12-06       Impact factor: 3.199

4.  Efficacy and safety of biologic agents and tofacitinib in moderate-to-severe ulcerative colitis: A systematic overview of meta-analyses.

Authors:  Katerina Pantavou; Anneza I Yiallourou; Daniele Piovani; Despo Evripidou; Silvio Danese; Laurent Peyrin-Biroulet; Stefanos Bonovas; Georgios K Nikolopoulos
Journal:  United European Gastroenterol J       Date:  2019-10-17       Impact factor: 4.623

Review 5.  Chromoendoscopy, Narrow-Band Imaging or White Light Endoscopy for Neoplasia Detection in Inflammatory Bowel Diseases.

Authors:  Ofir Har-Noy; Lior Katz; Tomer Avni; Robert Battat; Talat Bessissow; Diana E Yung; Tal Engel; Anastasios Koulaouzidis; Rami Eliakim; Shomron Ben-Horin; Uri Kopylov
Journal:  Dig Dis Sci       Date:  2017-09-30       Impact factor: 3.199

6.  CD169 Expressing Macrophage, a Key Subset in Mesenteric Lymph Nodes Promotes Mucosal Inflammation in Dextran Sulfate Sodium-Induced Colitis.

Authors:  Qiuting Li; Dan Wang; Shengyu Hao; Xiaolei Han; Yuan Xia; Xiangzhi Li; Yaoxing Chen; Masato Tanaka; Chun-Hong Qiu
Journal:  Front Immunol       Date:  2017-06-26       Impact factor: 7.561

7.  Anti-Oxidant, Pro-Oxidant and Anti-Inflammatory Effects of Unpolished Rice Relevant to Colorectal Cancer

Authors:  Prasit Suwannalert; Witchuda Payuhakrit; Thidarat Koomsang
Journal:  Asian Pac J Cancer Prev       Date:  2016-12-01

8.  The influence of experimental inflammation and axotomy on leucine enkephalin (leuENK) distribution in intramural nervous structures of the porcine descending colon.

Authors:  Slawomir Gonkowski; Krystyna Makowska; Jaroslaw Calka
Journal:  BMC Vet Res       Date:  2018-05-24       Impact factor: 2.741

9.  Evaluation of the detection of Toll-like receptors (TLRs) in cancer development and progression in patients with colorectal cancer.

Authors:  Ippokratis Messaritakis; Maria Stogiannitsi; Asimina Koulouridi; Maria Sfakianaki; Alexandra Voutsina; Afroditi Sotiriou; Elias Athanasakis; Evangelos Xynos; Dimitris Mavroudis; Maria Tzardi; John Souglakos
Journal:  PLoS One       Date:  2018-06-08       Impact factor: 3.752

Review 10.  Genomic characterization of colitis-associated colorectal cancer.

Authors:  Hitoshi Kameyama; Masayuki Nagahashi; Yoshifumi Shimada; Yosuke Tajima; Hiroshi Ichikawa; Masato Nakano; Jun Sakata; Takashi Kobayashi; Sumana Narayanan; Kazuaki Takabe; Toshifumi Wakai
Journal:  World J Surg Oncol       Date:  2018-07-02       Impact factor: 2.754

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.